Conferences
ESMO 2023: Phase II Trial Compares Tobemstomig Alone or with Tiragolumab vs. Atezolizumab in Untreated Metastatic Urothelial Cancer
October 22, 2023
ESMO 2023: Biomarkers of Treatment - Related Toxicity in Advanced Urothelial Carcinoma Patients Treated with Enfortumab Vedotin: Analysis of UNITE Study
October 22, 2023
ESMO 2023: Staging of Muscle-Invasive Bladder Cancer: The Impact of PET Imaging [PET-MUSE]
October 22, 2023
ESMO 2023: A Pooled Meta-Analysis of Salvage Nivolumab/Ipilimumab after Nivolumab in Patients with Advanced Renal Cell Carcinoma
October 22, 2023
ESMO 2023: EMBARK: Health-Related Quality of Life in nmHSPC Patients with High-Risk BCR
October 22, 2023
ESMO 2023: KEYNOTE-641 Phase 3: Pembrolizumab plus Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
October 22, 2023